Edward von Kenn
liked
1
Edward von Kenn
liked
$Volcon (VLCN.US)$ I don't understand why many people are selling low, deal already closed. It's time for rally
3
3
Edward von Kenn
liked
$Unity Software(U.US$ Washing up and down dishes is like wiping a window
Translated
1
1
Edward von Kenn
liked
$MicroCloud Hologram(HOLO.US$ when is it gonna reverse spilt?🤣
1
1
Edward von Kenn
commented on
$Solowin(SWIN.US$ It's funny. Obviously, no one on the right hand wants to line up to sell tickets, but whoever lines up on the left hand to buy tickets will sell them as many cheap tickets as they want, so it's not that obvious if they want to fake it, okay? Open a few trading accounts over there and sell them yourself to buy tickets at a lower price! What I hate most is that this kind of brainless person is playing with stocks!
Translated
2
4
Edward von Kenn
liked
$Unity Software(U.US$
Which of these two funds is accurate, Momo or Tiger, respectively? Also, do they both show that capital inflows are greater than outflows?
Which of these two funds is accurate, Momo or Tiger, respectively? Also, do they both show that capital inflows are greater than outflows?
Translated
![Capital inflows and outflows](https://sgsnsimg.moomoo.com/sns_client_feed/103897858/20240619/cdfc7a87bd5ddb08adcccaf8810b86cb.jpg/thumb?area=101&is_public=true)
![Capital inflows and outflows](https://sgsnsimg.moomoo.com/sns_client_feed/103897858/20240619/3e138762d178a1269a622a3b0516b512.jpg/thumb?area=101&is_public=true)
1
Edward von Kenn
liked
$Processa Pharmaceuticals(PCSA.US$
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
Processa Pharmaceuticals has announced positive results from their Phase 1b trial of NGC-Cap in gastrointestinal cancer patients. The trial involved 12 patients, with 66.7% achieving progression-free survival (PFS) ranging from 5 to 11 months. At the highest dose, all patients showed PFS, with tw...
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
Processa Pharmaceuticals has announced positive results from their Phase 1b trial of NGC-Cap in gastrointestinal cancer patients. The trial involved 12 patients, with 66.7% achieving progression-free survival (PFS) ranging from 5 to 11 months. At the highest dose, all patients showed PFS, with tw...
3
Edward von Kenn
liked